TY - JOUR
T1 - Altered expression of HSPA5, HSPA8 and PARK7 in spinocerebellar ataxia type 17 identified by 2-dimensional fluorescence difference in gel electrophoresis
AU - Lee, Li Ching
AU - Chen, Chiung Mei
AU - Chen, Fen Lin
AU - Lin, Pei Ying
AU - Hsiao, Ya Chin
AU - Wang, Pin Rong
AU - Su, Ming Tsan
AU - Hsieh-Li, Hsiu Mei
AU - Hwang, Ji-Chuu
AU - Wu, Chung Hsin
AU - Lee, Guan-Chiun
AU - Singh, Sher
AU - Lin, Yenshou
AU - Hsieh, Sen Yung
AU - Lee-Chen, Guey Jen
AU - Lin, Jung Yaw
N1 - Funding Information:
We thank the Clinical Proteomic Center of Chang Gung Memorial Hospital for the technical support. This work was supported by grants NSC-96-3112-B-003-006 and NSC 96-2311-B-182A-001 from the National Science Council, Executive Yuan, 96TOP001 from National Taiwan Normal University, and CMRGP 33108 from Chang Gung Memorial Hospital, Taipei, Taiwan.
PY - 2009/2
Y1 - 2009/2
N2 - Background: Expansion of the CAG repeat of the TATA-box binding protein (TBP) gene has been identified as the causative mutations in spinocerebellar ataxia 17 (SCA17). TBP is ubiquitously expressed in both central nervous system and peripheral tissues. The underlying molecular changes of SCA17 are rarely explored. Methods: To study the molecular mechanisms underlying SCA17, we generated stably induced isogenic 293 cells expressing normal TBP-Q36 and expanded TBP-Q61 and analyzed the expressed proteins using two-dimensional difference in gel electrophoresis (2D-DIGE), followed by mass spectrometry and immunoblotting. Results: Upon induction with doxycycline, the expanded TBP-Q61 formed aggregates with significant increase in the cell population at subG1 phase and cleaved caspase-3. Proteomics study identified a total of 16 proteins with expression changes greater than 1.5 fold. Among the 16 proteins, PARK7, GLRX3, HNRNPA1, GINS1, ENO1, HNRPK and NPM1 are increased, and SERPINA5, HSPA5, VCL, KHSRP, HSPA8, HNRPH1, IMMT, VCP and HNRNPL are decreased in cells expressing TBP-Q61 compared with those expressing TBP-Q36. The altered expression of HSPA5, HSPA8 and PARK7 were further validated by 2D and Western immunoblot analyses. Conclusions: The results illustrate the utility of proteomics to identify alterations of proteins which underlie pathogenesis of SCA17, and may serve as potential therapeutic targets.
AB - Background: Expansion of the CAG repeat of the TATA-box binding protein (TBP) gene has been identified as the causative mutations in spinocerebellar ataxia 17 (SCA17). TBP is ubiquitously expressed in both central nervous system and peripheral tissues. The underlying molecular changes of SCA17 are rarely explored. Methods: To study the molecular mechanisms underlying SCA17, we generated stably induced isogenic 293 cells expressing normal TBP-Q36 and expanded TBP-Q61 and analyzed the expressed proteins using two-dimensional difference in gel electrophoresis (2D-DIGE), followed by mass spectrometry and immunoblotting. Results: Upon induction with doxycycline, the expanded TBP-Q61 formed aggregates with significant increase in the cell population at subG1 phase and cleaved caspase-3. Proteomics study identified a total of 16 proteins with expression changes greater than 1.5 fold. Among the 16 proteins, PARK7, GLRX3, HNRNPA1, GINS1, ENO1, HNRPK and NPM1 are increased, and SERPINA5, HSPA5, VCL, KHSRP, HSPA8, HNRPH1, IMMT, VCP and HNRNPL are decreased in cells expressing TBP-Q61 compared with those expressing TBP-Q36. The altered expression of HSPA5, HSPA8 and PARK7 were further validated by 2D and Western immunoblot analyses. Conclusions: The results illustrate the utility of proteomics to identify alterations of proteins which underlie pathogenesis of SCA17, and may serve as potential therapeutic targets.
KW - 2D-DIGE
KW - HSPA5
KW - HSPA8
KW - PARK7
KW - Spinocerebellar ataxia type 17
KW - TBP expansion
UR - http://www.scopus.com/inward/record.url?scp=57949096490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57949096490&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2008.10.013
DO - 10.1016/j.cca.2008.10.013
M3 - Article
C2 - 19014922
AN - SCOPUS:57949096490
SN - 0009-8981
VL - 400
SP - 56
EP - 62
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 1-2
ER -